Preferred Label : Anti-CD352 Antibody-drug Conjugate SGN-CD352A;
NCIt synonyms : PBD-based Anti-CD352 Antibody-drug Conjugate SGN-CD352A; PBD-based Anti-CD352 ADC SGN-CD352A; PBD Dimer ADC SGN-CD352A; ADC SGN-CD352A;
NCIt related terms : SGN-CD352A;
NCIt definition : An antibody-drug conjugate (ADC) consisting of an engineered cysteine humanized monoclonal
antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) that is conjugated
to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD)
dimer, with potential antineoplastic activity. Upon administration of anti-CD352 ADC
SGN-CD352A, the antibody moiety targets the cell surface antigen CD352. Upon antibody/antigen
binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released.
In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on
opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication,
leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation
of CD352-overexpressing tumor cells. CD352, a tumor-associated antigen (TAA), is overexpressed
on a variety of cancers. Cysteine engineering of the monoclonal antibody allows for
a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.;
UNII : ZX1I49XP7L;
Molecule name : SGN-CD352A;
NCI Metathesaurus CUI : CL513495;
Origin ID : C131174;
UMLS CUI : C4329315;
Semantic type(s)
- concept_is_in_subset
- has_target
